EXELIXIS, INC.EXELEarnings & Financial Report
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
EXEL Q4 2026 Key Financial Metrics
Revenue
$598.7M
Gross Profit
$572.2M
Operating Profit
$235.2M
Net Profit
$244.5M
Gross Margin
95.6%
Operating Margin
39.3%
Net Margin
40.8%
YoY Growth
5.6%
EPS
$0.89
Financial Flow
EXELIXIS, INC. Q4 2026 Financial Summary
EXELIXIS, INC. reported revenue of $598.7M for Q4 2026, with a net profit of $244.5M (40.8% margin). Cost of goods sold was $26.5M, operating expenses totaled $337.0M.
Key Financial Metrics
| Total Revenue | $598.7M |
|---|---|
| Net Profit | $244.5M |
| Gross Margin | 95.6% |
| Operating Margin | 39.3% |
| Report Period | Q4 2026 |
EXELIXIS, INC. Annual Revenue by Year
EXELIXIS, INC. annual revenue history includes year-by-year totals (for example, 2026 revenue was $2.3B).
| Year | Annual Revenue |
|---|---|
| 2026 | $2.3B |
| 2025 | $2.2B |
| 2024 | $1.8B |
| 2023 | $1.6B |
| 2022 | $1.4B |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $425.2M | $637.2M | $539.5M | $566.8M | $555.4M | $568.3M | $597.8M | $598.7M |
| YoY Growth | 4.0% | 35.6% | 14.3% | 18.2% | 30.6% | -10.8% | 10.8% | 5.6% |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.80B | $2.77B | $2.96B | $2.95B | $2.84B | $2.68B | $2.82B | $2.84B |
| Liabilities | $675.7M | $653.4M | $684.9M | $703.5M | $706.2M | $644.5M | $662.8M | $683.1M |
| Equity | $2.13B | $2.12B | $2.28B | $2.24B | $2.13B | $2.03B | $2.16B | $2.16B |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $68.8M | $119.5M | $271.3M | $240.3M | $211.4M | $49.0M | $290.3M | $333.5M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M
BIO
BIO-RAD LABORATORIES, INC.
Revenue
$693.2M
Net Profit
$720.0M